213 results
Page 4 of 11
8-K
EX-99.1
tkcdzftu qn1gmy
13 Dec 21
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
7:40am
8-K
EX-99.1
29gojsxtu7
27 Oct 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
9:04am
8-K
EX-99.1
9tzz4yk omppub
24 Aug 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
8:29am
424B5
2mwo n83v
19 Aug 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
klvp0tiwcdnhp75
13 Aug 21
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
7:11am
8-K
EX-99.1
o4um115v5x0nlh76j
14 May 21
Bio-Path Holdings Reports First Quarter 2021 Financial Results
7:10am
8-K
EX-99.1
4ou7dx5i0uzk 8j4ch
14 Apr 21
Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting
12:00am
424B5
cp6cba0u2g4kls
17 Feb 21
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
qbn3t4fu 37ropgytlx
19 Nov 20
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
4:30pm
8-K
EX-10.1
y07szhlz0q99geijj
14 Jul 20
Entry into a Material Definitive Agreement
6:05am
424B5
xemd46f
14 Jul 20
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
nru6yiqhgskclwls
14 May 20
Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting
4:30pm